셀 사이CVM 주가

♻️ 재탕[RW] RW — FORM RW

[RW] RW — FORM RW

CEL-SCI Reports Fiscal Second Quarter 2026 Results

On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi...

♻️ 재탕[4] 내부자 거래 — PRIMARY DOCUMENT

CEL-SCI Q2 EPS $(0.67) Down From $(0.08) YoY

CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.67) per share. This is a 737.5 percent decrease over losses of $(0.08) per share from the same period last year.

Cel-Sci: Fiscal Q2 Earnings Snapshot

VIENNA, Va. — VIENNA, Va. — Cel-Sci Corp. on Friday reported a loss of $10.9 million in its fiscal second quarter. On a per-share basis, the Vienna, Virginia-based company said it had a loss...

[10-Q] 분기 실적 — FORM 10-Q

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

[4] 내부자 거래 — PRIMARY DOCUMENT

♻️ 재탕CEL-SCI Announces Closing of Public Offering

VIENNA, Va., May 13, 2026--CEL-SCI announces closing of public offering.